ストックスクリーナーアプリを入手
38.77
0.60%
0.275
前日終値:
$38.50
開ける：
$37.82
24時間の取引高:
961.07K
Relative Volume:
0.43
時価総額：
$5.89B
収益：
$3.44B
当期純損益:
$-8.30M
株価収益率:
-260.76
EPS:
-0.1487
ネットキャッシュフロー:
$43.30M
1週間 パフォーマンス:
-5.58%
1か月 パフォーマンス:
-5.63%
6か月 パフォーマンス:
+25.62%
1年 パフォーマンス:
-17.37%
1日の値動き範囲:
$37.61
$39.54
1週間の範囲:
$37.58
$40.67
52週間の値動き範囲:
$28.53
$56.22
Bruker Corp Stock (BRKR) Company Profile
Compare BRKR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BRKR
Bruker Corp
|
38.78 | 5.85B | 3.44B | -8.30M | 43.30M | -0.1487 |
|
ABT
Abbott Laboratories
|
110.80 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
369.69 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
92.36 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.02 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.28 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bruker Corp Stock (BRKR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-09 | 開始されました | Goldman | Sell |
| 2025-11-20 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-19 | 開始されました | Guggenheim | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-05 | アップグレード | Goldman | Sell → Neutral |
| 2024-10-15 | 開始されました | Barclays | Overweight |
| 2024-09-30 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2022-10-21 | 開始されました | UBS | Buy |
| 2022-08-22 | アップグレード | Citigroup | Neutral → Buy |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | アップグレード | Cleveland Research | Neutral → Buy |
| 2021-02-05 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-12-02 | 開始されました | Goldman | Sell |
| 2020-11-16 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2020-05-01 | ダウングレード | Cleveland Research | Buy → Neutral |
| 2020-04-02 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2020-04-01 | ダウングレード | Needham | Strong Buy → Hold |
| 2020-03-26 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-11-15 | 開始されました | Stifel | Hold |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-06-24 | 繰り返されました | Needham | Strong Buy |
| 2019-06-21 | 繰り返されました | BofA/Merrill | Neutral |
| 2019-05-30 | 開始されました | Wolfe Research | Peer Perform |
| 2019-05-06 | 繰り返されました | Needham | Strong Buy |
| 2019-05-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-03 | アップグレード | UBS | Sell → Neutral |
| 2019-04-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2019-02-12 | 繰り返されました | BTIG Research | Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
すべてを表示
Bruker Corp (BRKR) 最新ニュース
Bruker Corp To Go Ex-Dividend On March 23rd, 2026 With 0.05 USD Dividend Per Share - 富途牛牛
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers - Finviz
BRKRP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BRKR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Artisan Partners Limited Partnership Invests $13.69 Million in Bruker Corporation $BRKR - MarketBeat
Bruker Corp. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
BRKR PE Ratio & Valuation, Is BRKR Overvalued - Intellectia AI
Beyond the Balance Sheet: What SWOT Reveals About Bruker Corp (B - GuruFocus
Bruker (NASDAQ: BRKR) outlines 2025 business segments, risks and $2.57B backlog - Stock Titan
Bruker (BRKR): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics With the Launch of CellScape XR - 富途牛牛
Is Bruker (BRKR) Now Offering Value After A Prolonged Share Price Slump? - Yahoo Finance
Bruker Corporation (NASDAQ:BRKR) Given Average Rating of "Hold" by Brokerages - MarketBeat
New Bruker tool targets 3,000-patient tumor study in spatial proteomics - Stock Titan
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR - Yahoo Finance
Reasons Why Bruker Corporation (BRKR) Appears So Attractive - Finviz
Inside Bruker and Noetik’s push toward 1B mapped human cells - Stock Titan
Bruker unveils spatial biology platforms at AGBT conference - Investing.com
Bruker unveils spatial biology platforms at AGBT conference By Investing.com - Investing.com Canada
Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum – Company Announcement - Financial Times
Bruker taps AI to map disease proteins for new drug targets - Stock Titan
Bruker announces board changes and declares quarterly dividend By Investing.com - Investing.com South Africa
Bruker announces board changes and declares quarterly dividend - Investing.com
Envestnet Asset Management Inc. Sells 43,490 Shares of Bruker Corporation $BRKR - MarketBeat
3D Protein Structure Analysis Market Report 2026 Featuring - GlobeNewswire
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players - Yahoo Finance UK
The Top 5 Analyst Questions From Bruker's Q4 Earnings Call - Finviz
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday - Intellectia AI
The Top 5 Analyst Questions From Bruker’s Q4 Earnings Call - Yahoo Finance
Bruker (BRKR) executive exercises options and sells 2,000 shares - Stock Titan
Don't Overlook Bruker (BRKR) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bruker Corp (BRKR) Shares Up 3.12% on Feb 17 - GuruFocus
Institutional Orbis investors report 9.8% Bruker (NASDAQ: BRKR) ownership stake - Stock Titan
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down - Nasdaq
US$48.43: That's What Analysts Think Bruker Corporation (NASDAQ:BRKR) Is Worth After Its Latest Results - 富途牛牛
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report - simplywall.st
These analysts cut their forecasts on Bruker following Q4 results - MSN
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP) and Bruker (BRKR) - The Globe and Mail
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $35 to $49 - 富途牛牛
Can Bruker Corporation expand into new marketsPortfolio Gains Summary & Stepwise Trade Execution Plans - mfd.ru
A Look At Bruker (BRKR) Valuation After Mixed Earnings And Soft 2026 Growth Outlook - Yahoo Finance
Bruker’s 2025 Earnings Call Maps a Cautious Recovery - TipRanks
Forecasting The Future: 15 Analyst Projections For Bruker - Benzinga
Bruker (BRKR) Price Target Lowered by Citigroup, Rating Maintained | BRKR Stock News - GuruFocus
TD Cowen Issues Pessimistic Forecast for Bruker (NASDAQ:BRKR) Stock Price - MarketBeat
These Analysts Cut Their Forecasts On Bruker Following Q4 Results - Benzinga
Bruker (BRKR) Target Price Adjustment: Barclays Lowers Price Tar - GuruFocus
Bruker (BRKR) Is Down 8.6% After Mixed 2025 Results and Cautious 2026 Guidance Has The Bull Case Changed? - Yahoo Finance
Bruker Corporation (NASDAQ:BRKR) Q4 2025 Earnings Call Transcript - Insider Monkey
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $40 to $53 - 富途牛牛
Earnings call transcript: Bruker Q4 2025 earnings miss, stock drops 14% By Investing.com - Investing.com South Africa
Bruker Corp (BRKR) 財務データ
収益
当期純利益
現金流量
EPS
Bruker Corp (BRKR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Munch Mark | EXEC VP&PRES BRUKER NANO INC. |
Feb 13 '26 |
Sale |
36.94 |
2,000 |
73,880 |
128,443 |
2.66%
大文字化:
|
ボリューム (24 時間):